R ecent reports suggest that atrial fibrillation (AF) is associated with the activation of the atrial angiotensin system. Pedersen et al 1 provided the first evidence that angiotensin-converting enzyme (ACE) inhibitor therapy can reduce the occurrence of AF in patients with left ventricular dysfunction after myocardial infarction. In addition, Van den Berg et al 2 observed that pretreatment with ACE inhibitors reduced the relapse rate of AF after electrical cardioversion. Thus, the inhibition of the cardiac angiotensin system by ACE inhibitors/angiotensin receptor antagonists might affect the pathophysiological substrate of AF and may offer a new therapeutic approach. However, the atrial expression of angiotensin II type 1 and type 2 receptors (AT 1 -R and AT 2 -R) has not been investigated in patients with AF.
The purpose of the present study was to localize atrial AT 1 -R/AT 2 -R and to quantify the expression of these receptors at the protein and mRNA level in patients with and without AF.
Methods

Patients
After written informed consent was obtained, right atrial appendages were obtained from patients undergoing cardiac bypass surgery or mitral/aortic valve replacement. Tissue samples were taken from 11 consecutive patients with chronic, persistent AF (Ն6 months; cAF) and from 11 matched patients with no history of AF (sinus rhythm [SR] ). In addition, 8 consecutive patients with documented episodes of paroxysmal AF (pAF; 3Ϯ2 AF episodes per month) were studied (Table) .
Western Blotting
Tissue samples were homogenized in 2ϫ RotiLoad (Roth) using an UltraTurrax. Aliquots of 300 g were separated in 4% to 12% gradient SDS-polyacrylamide gels (Novex Electrophoresis) and transferred onto nitrocellulose membrane BA85 (Schleicher & Schüll). Rabbit anti-AT 1 -R and anti-AT 2 -R polyclonal antibodies (Biotrend), goat-anti-rabbit-peroxidase (New England Biolabs), and SuperSignal West Dura Extended Duration Substrate (Pierce) were used for immunodetection. The resulting images were densitometrically analyzed. The mean relative absorption units of the control group were compared with the corresponding means of the AF groups. Comparison of the different groups was only done on blots processed equally and exposed on the same x-ray film.
Quantitative Polymerase Chain Reaction
One microgram of total RNA, which was prepared using TRIZOL (Gibco BRL), was reverse-transcribed. A total of 5% of the cDNA mixture was used for quantitative polymerase chain Amounts of 18S-mRNA were used to normalize cDNA contents. Initial denaturation at 95°C for 3 s was followed by 40 cycles with denaturation at 95°C for 0 s, annealing at 65°C (AT 1 -R) or 60°C (AT 2 -R) for 3 s, and elongation at 72°C for 15 s (AT 1 -R) or 9 s (AT 2 -R). The fluorescence intensity, which reflected the amount of actually formed PCR product, was read at the end of each elongation step. Initial amounts of template mRNA were calculated by determining the time point at which the linear increase of PCR product started, relative to the corresponding points of a standard curve.
Histochemistry and Immunohistochemistry
Histochemistry and immunohistochemistry for localization of AT-Rs were performed in a total of 15 tissue specimens (4 SR, 6 cAF, 5 pAF). Sections from formalin-fixed and paraffin-embedded specimens were stained with hematoxylin and eosin. Immunostaining was performed with antibodies, as specified above, directed against AT 1 -R or AT 2 -R (dilution 1:20) following standard protocols. The specificity was controlled by omitting the primary antibody. 
Patient Characteristics
⅐ ⅐ ⅐ As, B, C M 7 5 ⅐ ⅐ ⅐ 3 MR 35 4.7 ⅐ ⅐ ⅐ A, As, L, N M 5 9 ⅐ ⅐ ⅐ ⅐ ⅐ ⅐ AR 45 NA ⅐ ⅐ ⅐ D, L M 6 7 ⅐ ⅐ ⅐ 3 AS 25 4.67 ⅐ ⅐ ⅐ As, B, C M 7 6 ⅐ ⅐ ⅐ ⅐ ⅐ ⅐ AS 38
Statistical Analysis
All values are expressed as meanϮSD. Differences between the 3 groups of patients were evaluated using 1-way ANOVA. PϽ0.05 was considered statistically significant.
Results
AT 1 -R and AT 2 -R
The relative amount of AT 1 -R in atrial tissue was significantly reduced in patients with cAF (34.9Ϯ40.9%; nϭ11; PϽ0.01) and pAF (51.7Ϯ26.6%; nϭ8; PϽ0.05) compared with patients with SR (100Ϯ58.1%; nϭ11). The difference between pAF and cAF was not significant (Figure, A) . The amount of AT 1 -R correlated neither with AF duration nor with left ventricular ejection fraction (r 2 ϭ0.03 and r 2 ϭ0.02, respectively; PϭNS). AT 2 -R was increased in patients with pAF (505Ϯ331.6%; nϭ11; PϽ0.01) compared with patients with SR (100Ϯ108.8%; nϭ11). The observed increase in patients with cAF (246Ϯ323.2%; nϭ11) did not reach statistical significance.
AT 1 -R and AT 2 -R mRNA
The amount of AT 1 -R mRNA was not different in patients with cAF (85.7Ϯ80.4%; nϭ11) or pAF (65Ϯ36%; nϭ8) compared with patients in SR (100Ϯ86.5%; nϭ11). AT 2 -R mRNA content was not significantly increased during cAF (179.9Ϯ156.8%; nϭ11) or pAF (126.2Ϯ101.4%; nϭ8) compared with patients with SR (100Ϯ60.5%; nϭ11; Pϭ0.4).
Immunohistochemistry
The spatial distribution of AT-R showed no differences between patients with and without AF. 
Discussion
The action of angiotensin II is initiated by binding to AT 1 -R/AT 2 -R. 3, 4 Stimulation of AT 1 -R induces myocardial hypertrophy and the accumulation of extracellular matrix proteins; it can also affect atrial contractility. 3, 4 In contrast, stimulation of AT 2 -R inhibits proliferative processes. 5 Our study describes, for the first time, the regulation of atrial AT 1 -R/AT 2 -R expression in patients with AF. pAF and cAF were associated with the down-regulation of AT 1 -R. An up-regulation of AT 2 -R was observed during pAF. In contrast, at the mRNA level, AT 1 -R/AT 2 -R expression was not significantly altered.
AF is associated with progressive structural changes of the atria, resulting in atrial dilation and loss of transport function. 1, 2 A previous study demonstrated that the atrial expression of ACE is increased in patients with AF, possibly leading to angiotensin II-dependent progressive atrial fibrosis. 6 Increased angiotensin II tissue levels during AF may trigger the observed down-regulation of AT 1 -R. A reduction of AT 1 -R and an increase of AT 2 -R may, therefore, be compensatory to inhibit the progression of angiotensin II-dependent interstitial fibrosis.
The atrial expression of ACE and AT-R subtypes during AF resembles changes seen in patients with terminal left ventricular failure. 3, 4, 6 Rogg et al 3 showed that the atrial expression of AT 1 -R is positively correlated with left ventricular ejection fraction, whereas left ventricular ejection fraction and AT 2 -R are inversely related. In the present study, however, none of the patients had terminal heart failure. One can, therefore, hypothesize that the regulatory changes seen during AF characterize the presence of an "end-stage atrial myopathy." This is supported by other studies, 1, 2, 6 which have shown the development of severe morphological/functional atrial abnormalities during cAF.
The observed changes in amounts of AT-R proteins, despite the unaltered corresponding mRNA levels, suggest that the expression of AT-R subtypes is regulated by posttranscriptional mechanisms. Underlying regulatory processes may encompass inefficient AT-R mRNA translation or decreased AT-R stability. 7 In conclusion, this study shows that cAF and pAF are associated with significant changes in the atrial expression of AT 1 -R/AT 2 -R. Further studies must define possible therapeutic consequences.
